TICKERNERD
Menu
MBXMBXHealthcare · Biotechnology

MBX Stock Forecast: MBX Biosciences, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$63
−1.53% on the day

The 11 Wall Street analysts covering MBX Biosciences, Inc. hold a median 12-month price target of $88 — +39.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.0B
Ticker Nerd rank
37 / 100
Median analyst target
$88
Analysts covering
11
Revenue$0.0
Operating income−$40.9M
Net income−$37.1M
Free cash flow−$23.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.6%
1M
−5.4%
YTD
+99.5%
1Y
+524.7%
From 52W high
−11.0%
From 52W low
+529.1%
$10
$71
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MBX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MBX Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Value
76
Quality
53
Accruals
44
Growth
38
Revisions
35
Size
30
Issuance
24
Volatility
13

Momentum (98): The shares have been drifting up relative to others.

Volatility (13): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MBX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MBX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100$120Oct 25Jan 26Apr 26Jul 26MBXHigh $121Median $88Low $70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $70Median $88High $121

The green dot is the last close — the median target sits +39.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
21 Aug 2026JP MorganReinstatesOverweight$88
10 Aug 2026Truist SecuritiesMaintainsBuy$70 → $88
10 Aug 2026Truist SecuritiesMaintainsBuy—
29 July 2026MizuhoMaintainsOutperform—
29 July 2026MizuhoMaintainsOutperform$57 → $91
12 May 2026BarclaysMaintainsOverweight$66 → $70
12 May 2026BarclaysMaintainsOverweight—
12 May 2026CitizensMaintainsMarket Outperform$76 → $86
12 May 2026CitizensMaintainsMarket Outperform—
11 May 2026Truist SecuritiesMaintainsBuy—
11 May 2026Truist SecuritiesMaintainsBuy$50 → $70
28 Jan 2026BarclaysInitiatesOverweight—
16 Jan 2026GuggenheimMaintainsBuy—
7 Jan 2026UBSInitiatesBuy—
19 Dec 2025StifelMaintainsBuy—
4 Dec 2025Goldman SachsInitiatesSell—
10 Nov 2025GuggenheimMaintainsBuy—
4 Nov 2025TD CowenInitiatesBuy—
15 Oct 2025Truist SecuritiesInitiatesBuy—
24 Sept 2025MizuhoMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MBX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MBX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, MBX Biosciences, Inc. returned +524.7% against +16.3% for the S&P 500, dividends included.

MBX vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500600700Oct 25Jan 26Apr 26Jul 26MBXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MBX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

MBX Biosciences, Inc. (MBX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.7×

Cheaper than 67% of US stocks

Price / sales
—
Price / book
7.4×

Cheaper than 13% of US stocks

EV / EBITDA
−22.2×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−33.2%

Higher than 26% of US stocks

Return on assets
−22.1%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MBX Biosciences, Inc. (MBX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MBX Biosciences, Inc. has a market value of $3.0B and an enterprise value of $2.6B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$104.3M.

  • Diluted earnings per share, trailing twelve months: $−2.40.

  • Free cash flow in the twelve months to 30 June 2026: −$85.2M.

  • Shares outstanding: 47.9M.

  • Trailing P/E: 3.7×; forward P/E: −15.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • MBX Biosciences, Inc. employs 63 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

MBX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MBXMBX Biosciences, Inc.$3.0B
37
QUREUniQure NV$3.0B
57
CLDXCelldex Therapeutics, Inc.$2.9B
29
DNLIDenali Therapeutics, Inc.$3.1B
57
RCUSArcus Biosciences, Inc.$3.1B
58
DYNDyne Therapeutics, Inc.$3.1B
23
ARQTArcutis Biotherapeutics, Inc.$3.1B
89

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MBX Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MBX news & analysis

MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

MBX Biosciences, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The item provides access to the company's conference remarks.

Why it matters — MBX watchers can review the company's latest management commentary from a major investor conference for insight into its positioning.

MBX Biosciences to Participate in Upcoming Investor Conferences

GlobeNewsWire · 9 Sept 2026neutral

MBX Biosciences announced that CEO Steve Hoerter and Chief Medical Officer Sam Azoulay will present at and participate in several upcoming investor conferences. The company is a clinical-stage biopharmaceutical firm developing precision peptide therapies for endocrine and metabolic disorders.

Why it matters — This provides MBX watchers with opportunities to hear directly from leadership about the company's pipeline and strategy at investor events.

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer

GlobeNewsWire · 8 Sept 2026neutral

MBX Biosciences announced the appointment of Jeff Held as Chief Legal Officer, based in Carmel, Indiana and Burlington, Massachusetts. The news was distributed via GlobeNewsWire.

Why it matters — MBX watchers may view the addition of a new chief legal officer as a leadership strengthening move for the company's corporate and legal affairs.

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

GlobeNewsWire · 27 Aug 2026positive

MBX Biosciences announced that the first patient has been dosed in its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide for adults with hypoparathyroidism. The trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit.

Why it matters — This marks the advancement of MBX's lead candidate into a pivotal Phase 3 study, a key step toward potential regulatory development for hypoparathyroidism.

FAQ

Frequently asked questions about MBX stock

What is the MBX stock price forecast for 2026-2027?

The 11 Wall Street analysts covering MBX Biosciences, Inc. have a median 12-month price target of $88, with estimates ranging from $70 to $121. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MBX stock a buy right now?

Of the 11 analysts covering MBX Biosciences, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MBX Biosciences, Inc. 37 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MBX?

As at 19 Sept 2026, MBX Biosciences, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will MBX stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +39.9% from the last close, and Ticker Nerd's factor model ranks MBX Biosciences, Inc. 37 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MBX stock forecast for 2030?

No analyst covering MBX Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $121 over the next 12 months.

How has MBX stock performed over the past year?

MBX Biosciences, Inc. returned +524.7% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MBX Biosciences, Inc. do?

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders.

What is the latest news on MBX?

The most recent item we track (Seeking Alpha, 16 Sept 2026): "MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". MBX Biosciences, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The item provides access to the company's conference remarks.

Company

About MBX Biosciences, Inc.

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. MBX Biosciences is advancing investigational programs built around its proprietary peptide platform to address conditions such as chronic hypoparathyroidism, post-bariatric hypoglycemia, and obesity. Its pipeline includes canvuparatide, a parathyroid hormone replacement candidate, as well as additional peptide-based assets in clinical and preclinical development. The company’s work centers on designing long-acting therapies intended to improve treatment convenience and expand options in specialty endocrine care. Based in Carmel, Indiana, MBX Biosciences operates in the biotechnology and specialty therapeutics market, where it contributes to the development of targeted medicines for diseases with significant unmet medical needs.

CEO Mr. Steven L. Hoerter · 63 employees · United States · https://mbxbio.com